Hunterdon Pharmaceuticals Incsaid it formed a joint venture with &lt;Chesapeake BiologicalLaboratories> and &lt;E.B. Michaels Research Associates> todevelop C31G, a substance that may be useful in the treatmentor prevention of plaque.    The substance, tested in pre-clinical trials at theUniversity of Pennsylvania, also has other uses as ananti-fungal or anti-bacterial agent, the company said.    It said Chesapeake Biological, a private company, owns 55pct of the venture, E.B. Michaels 10 pct, while it holds theremaining interest, and the patent for C31G. Reuter&#3;